Department of Psychiatry

Penn Behavioral Health

HVTN 104

About the Study

This is a study designed to test the safety and tolerability of an anti-HIV monoclonal antibody known as VRC01. This monoclonal antibody will be further studied in upcoming research to see if it works to prevent high risk people from becoming HIV infected. Low risk partiipants will receive the monoclonal antibody or placebo by subcutaneous injection or intravenous infusion at set intervals, and then maintain a diary of how they are feeling for 3 days following the receipt of the study drug.

Protocol Title

HVTN 104 A phase 1 clinical trial to evaluate the safety and drug levels of a human monoclonal antibody, VRC HIVMAB060 00 AB (VRC01) administered in multiple doses intravenously and subcutaneously in different dosing schedules to healthy, HIV uninfected adults

Principal Investigator

Ian Frank, MD
3535 Market St., 4th floor, Ste 4000


David S. Metzger, PhD
3535 Market St., 4th floor, Ste 4000

Debora Dunbar, MSN, CRNP
3535 Market St., 4th floor, Ste 4000

Back to Top